11
is to improve the lives of patientsby developing innovative treatments
that address important unmet patient needs.
OUR
MISSION
OUR
MISSIONWe develop patient-focused solutions by applying our innovative technologies to therapeutic agents with well-known pharmacology, with the goal of making our products: • More effective than other pharmaceutical agents in the same class
• Safer or better tolerated than other pharmaceutical agents in the same class
• Better able to address the multiple pathways of a disease or disorder through
new mechanisms of action and delivery
• Potentially able to reduce the dependence on other classes of drugs with more
harmful side effects, such as opioids
HERON THERAPEUTICS
COMPANY TIMELINE
January• Company changes name to
Heron Therapeutics, Inc.• New Board of Directors is appointed• Heron is relisted on NASDAQ Capital
Market trading under symbol HRTX
March• Launches Phase 3 MAGIC
study of SUSTOL®
May• HTX-011 demonstrates positive
preclinical data and moves to clinical development
June• Heron joins Russell 3000 Index• $59.8M Underwritten Offering
of Common Stock closes
November• Discloses development
program for CINVANTI™ (HTX-019), NK1 for CINV
May• Heron reports positive
top-line data for SUSTOL® from Phase 3 MAGIC study
2014 2015 2016 2017June• HTX-011 enters Phase 2 development• $128.2M Underwritten Offering
of Common Stock closes
September• Heron reports positive
top-line data for HTX-011 from first Phase 2 study
July• Heron resubmits NDA
for SUSTOL® to FDA
August• US FDA approves SUSTOL® (granisetron)
extended-release injection• HTX-011 demonstrates Phase 2 efficacy
for pain management after hernia surgery
December• Partners with Susan G. Komen
to raise awareness for the importance of supportive care in the treatment of breast cancer
January• Heron submits NDA for CINVANTI™ to FDA• Announces best-in-class Phase 2 data for
HTX-011 in postoperative pain• $163.7M Underwritten Offering of Common
Stock closes
October• HTX-011 Fast Track designation
granted by US FDA
August• Initiated Phase 3 program for HTX-011 after
successful End-of-Phase 2 meeting with FDA• Raised SUSTOL guidance for 2017 reflecting
strong sales and successful launch in first half of 2017
February• SUSTOL included as a Category 1
therapeutic option in the NCCN Guidelines for acute and delayed emesis due to HEC and MEC
November• US FDA approves
CINVANTI™ (aprepitant) injectable emulsion
HERON THERAPEUTICS
COMPANY TIMELINE (CONT)
January• Company changes name to
Heron Therapeutics, Inc.• New Board of Directors is appointed• Heron is relisted on NASDAQ Capital
Market trading under symbol HRTX
March• Launches Phase 3 MAGIC
study of SUSTOL®
May• HTX-011 demonstrates positive
preclinical data and moves to clinical development
June• Heron joins Russell 3000 Index• $59.8M Underwritten Offering
of Common Stock closes
November• Discloses development
program for CINVANTI™ (HTX-019), NK1 for CINV
May• Heron reports positive
top-line data for SUSTOL® from Phase 3 MAGIC study
2014 2015 2016 2017June• HTX-011 enters Phase 2 development• $128.2M Underwritten Offering
of Common Stock closes
September• Heron reports positive
top-line data for HTX-011 from first Phase 2 study
July• Heron resubmits NDA
for SUSTOL® to FDA
August• US FDA approves SUSTOL® (granisetron)
extended-release injection• HTX-011 demonstrates Phase 2 efficacy
for pain management after hernia surgery
December• Partners with Susan G. Komen
to raise awareness for the importance of supportive care in the treatment of breast cancer
January• Heron submits NDA for CINVANTI™ to FDA• Announces best-in-class Phase 2 data for
HTX-011 in postoperative pain• $163.7M Underwritten Offering of Common
Stock closes
October• HTX-011 Fast Track designation
granted by US FDA
August• Initiated Phase 3 program for HTX-011 after
successful End-of-Phase 2 meeting with FDA• Raised SUSTOL guidance for 2017 reflecting
strong sales and successful launch in first half of 2017
February• SUSTOL included as a Category 1
therapeutic option in the NCCN Guidelines for acute and delayed emesis due to HEC and MEC
November• US FDA approves
CINVANTI™ (aprepitant) injectable emulsion
OUR PRODUCTS AND
PIPELINEWe develop novel, patient-focused solutions that apply our innovative science and technologies, such as our proprietary Biochronomer® drug delivery technology, to approved pharmacological agents.
We are currently developing and commercializing pharmaceutical products for patients suffering from cancer or postoperative pain:
OUR PRODUCTS AND
PIPELINE
NDAClinical Approved
SUSTOL®
(granisetron) extended-release injection
CINVANTI™(aprepitant) injectable emulsion
HTX-011bupivacaine and meloxicam ER Local Administration
HTX-011bupivacaine and meloxicam ER Nerve Block
Approved by US Food and Drug Administration
Post-Op Pain in Local Administration
Post-Op Pain in Nerve Block
• Fast Track designation granted• Phase 3 program underway
Phase 2 program in nerve block underway
Chemotherapy-induced Nausea and Vomiting (CINV) Pain Management
Approved by US Food and Drug Administration
We are committed and focused on maximizing patient care, from CINV prevention to postoperative pain management.Robert H. Rosen, President
• SUSTOL® (granisetron) extended-release injection, which incorporates Biochronomer® technology, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens
• CINVANTI™ (aprepitant) injectable emulsion is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)
• HTX-011 leverages meloxicam in a novel combination with bupivacaine to potentiate a powerful local analgesic effect, delivered over 72 hours via the Biochronomer® technology
OUR PRODUCTS AND
PIPELINE
VALUES
Improve care and quality of life by developing innovative therapies that fill unmet patient needs
• We put the needs of our patients first
• We do the right thing
• We are results driven and accountable
• We communicate transparently
• We work respectfully
OUR
VALUES The goal for everyone at Heron Therapeutics is to develop best-in-class medicines that have the potential to significantly improve the lives of patients suffering with the debilitating effects of chemotherapy and acute pain. Helping patients is at the core of everything we do.
Barry D. Quart, PharmD., Chief Executive Officer
© 2018 Heron Therapeutics, Inc. All rights reserved. 1/18 herontx.com
